EUCTR2012-003507-35-ES进行中（未招募）不适用
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 147
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. ? 18 year old females
- •2. Subjects with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC)
- •3. Histologically or cytologically confirmed TNBC; Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epithelial Receptor-2 (HER2) negative by IHC. For ER and PR, a score of <1% positive nuclei will be considered negative. A HER2 IHC score of 0 or 1+ is considered negative. A HER2 IHC score of 2+ will be considered negative only if verified by FISH. Local laboratory analysis will be used for eligibility; central laboratory confirmation will be performed retrospectively.
- •4. Measurable disease per Response Evaluation Criteria in Solid Tumors [RECIST], Version 1.1.
- •5. ECOG performance status of 0 or 1.
- •6. A female is eligible to participate if she is of non-childbearing potential or has documentation of a negative pregnancy test within 7 days prior to the start of the study treatment. Sexually active pre-menopausal female subjects must agree to use adequate, highly effective contraceptive measures, while on study and for 30 days after the last dose of last study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) oral, implantable or injectible contraceptive plus one barrier method; or (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
- •7. Confirmed available archival tumor tissue. If more than one biopsy is available, the most recent is preferred.
- •8. Ability to give written informed consent and comply with protocol requirements, including drug treatments and follow-up procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 103
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •1. Any prior systemic therapy (including chemotherapy, signal transduction inhibitors and monoclonal antibodies, immunotherapy, bevacizumab, any investigational or licensed drug that targets VEGF or VEGF receptors/pathway or are mammalian target of rapamycin [mTOR] inhibitors) for treatment of advanced or mBC.
- •2. Major surgical procedure within 4 weeks prior to administration of first dose of study drug; radiotherapy or minor surgical procedure within 2 weeks prior to administration of first dose of study drug; inadequate recovery from prior therapy or surgical procedure;
- •3. Untreated central nervous system metastases
- •Note: Subjects with previously treated (radiotherapy or surgery) brain metastasis that have been stable off steroids or enzyme-inducing anti-epileptic drugs for at least 3 months following prior treatment may be enrolled.
- •4. Any of the following hematologic and coagulation abnormalities:
- •? Hemoglobin < 9.0 g/dL;
- •? Absolute neutrophil count (ANC) < 1500 per mm3;
- •? Platelet count < 100,000 per mm3;
- •5. Any of the following serum chemistry and urinalysis abnormalities:
- •? Total bilirubin > 1.5 × ULN;
- •? Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis);
- •? Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis);
- •? Creatinine > 2.0 × ULN;
- •? Proteinuria > 2+ by urinalysis or urine dipstick.
- •6. Significant cardiovascular disease, including:
- •? Symptomatic Left Ventricular Dysfunction or Baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) of <50%;
- •? Uncontrolled hypertension: systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart;
- •? Myocardial infarction, or unstable angina within 6 months prior to administration of first dose of study drug;
- •? History of Class III or IV congestive heart failure, as defined by the New York Heart Association;
- •? History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation);
- •? Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication; and/or
- •? Coronary or peripheral artery bypass graft within 6 months of screening.
- •7. Severe peripheral neuropathy, defined as ? Grade 2 (per CTCAE Version 4.0)
- •8. Non-healing wound, bone fracture, or skin ulcer
- •9. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug.
- •10. Serious/active infection or infection requiring parenteral antibiotics
- •11. Significant arterial or venous thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, including but not limited to:
- •? Deep vein thrombosis;
- •? Pulmonary embolism
- •? Cerebrovascular accident (CVA) or transient ischemic attack (TIA);
- •? Peripheral ischemia > Grade 2 (per CTCAE Version 4.0).
- •12. Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:
- •? Hematemesis, hematochezia, melena or other gastrointestinal bleeding ? Grade 2 (per CTCAE Version 4.0);
- •- Hemoptysis or other pulmonar
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 In Duchenne Muscular DystrophyEUCTR2014-002072-92-ITPfizer Inc. 235 East 42nd Street, New York, NY 10017105
招募中
1 期
A Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with SBMASpinal and Bulbar Muscular AtrophyMedDRA version: 20.0Level: LLTClassification code: 10068600Term: Kennedy's disease Class: 10010331CTIS2023-507128-22-00ido Biosciences Inc.54
进行中（未招募）
1 期
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003140-83-NLeurocrine Biosciences, Inc.60
进行中（未招募）
1 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's DiseaseCrohn's DiseaseEUCTR2017-001976-48-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO240
进行中（未招募）
不适用
This is a clinical research study involving an experimental drug named GS-6624 for the treatment of metastatic colorectal adenocarcinoma, a sub-type of cancer of the colon and/or rectum. The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with FOLFIRI. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic colorectal adenocarcinoma when it is given with FOLFIRI.EUCTR2011-003754-61-ESGilead Sciences, Inc.265